Groupe Berkem announces 2023 Full-Year Revenue of €52.4 million

Regulatory News:

Groupe Berkem, a leading player in bio-based chemistry (ISIN code: FR00140069V2 – Ticker: ALKEM), today announces its consolidated 2023 full-year revenue, as at December 31, 2023.

Olivier FAHY, Chairman and CEO of Groupe Berkem, stated: "Despite a financial year marked by significant tensions in some of its historic markets, Groupe Berkem proved the resilience of its business model throughout the year. The investments in R&D, business development and acquisitions that we have initiated and intend to pursue, demonstrated their potential in 2023. This was particularly the case in our "Health, Beauty & Nutrition" business area, with the numerous product launches we carried out, and in our "Industry" business area, which is being structured to better address the growing needs of manufacturers for innovative biobased solutions capable of integrating conventional chemistry. As was the case for i.Bioceuticals and Biopress in 2023, the Givaudan industrial site whose acquisition we are announcing today should enable us to move into new growth markets and significantly increase our current production capacities. The coming year should therefore be marked by new investments aimed at ensuring the ramp-up of this new site, offering the Group a new development outlook and positioning it even more as a leader in plant chemistry for the benefit of all industries, in France and internationally.”

In millions of euros – IFRS standards1	2023	2022	Change
First-Quarter Revenue	14.5	13.8	+5.1%
Second-Quarter Revenue	13.4	14.4	-1.0%
Third-Quarter Revenue	12.0	11.6	+3.5%
Fourth-Quarter Revenue	12.6	11.9	+5.0%
12-months total
Construction & Materials	22.3